This study evaluated the efficacy, safety and impact on quality of life (QoL) of a dose-dense biweekly regimen of docetaxel and 5-fluorouracil in first-line treatment of advanced gastric cancer (AGC). This novel regimen is a promising option for AGC, showing high RR, improvement on QoL and acceptable toxicity.

READ FULL ARTICLE Curated publisher From Mdlinx